TAIMEI TECH (02576) plans to repurchase H shares according to the general authorization to repurchase H shares.

date
23:07 23/06/2026
avatar
GMT Eight
Taimai Medical Technology (02576) announced that the shareholders of the company have been granted a general authorization by the Board of Directors at the annual general meeting held on June 23, 2026 to repurchase the company's H shares. Under the H shares repurchase authorization, depending on market conditions and the company's actual situation, the company may from time to time repurchase its H shares on the Stock Exchange.
TAIMEI TECH (02576) announced that the company's shareholders granted the Board of Directors a general authorization to repurchase the company's H shares at the annual general meeting held on June 23, 2026. Under the H share buyback authorization, subject to market conditions and the company's actual situation, the company may, from time to time, repurchase its H shares on the Stock Exchange of Hong Kong. According to the H share buyback authorization, the company is authorized to repurchase H shares during the relevant period in an amount not exceeding 10% of the total number of H shares issued by the company on the day the H share buyback authorization was granted (excluding any treasury shares of the company). Pursuant to Listing Rule 10.06(2), the purchase price of H shares each time shall not be higher than 5% or more above the average closing price of the H shares on the five trading days immediately preceding the relevant buyback. Subject to the above limitations, the Board of Directors has decided that the repurchase price per H share shall not exceed HK$11, and the Board will determine the specific repurchase price based on market conditions and the company's actual situation. The Board of Directors believes that, depending on the market conditions and funding arrangements at the time, repurchasing H shares can enhance the net asset value and/or earnings per share of the company, enhance investor confidence in the company, and help maintain the company's reputation in the capital market and have a positive impact. The buyback will only proceed if the Board of Directors believes that it will be beneficial to the company and its shareholders as a whole.